{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:49:39Z","timestamp":1788839379471,"version":"build-2803163510"},"reference-count":0,"publisher":"Frontline Medical Communications, Inc.","issue":"Supplemental 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,1]]},"DOI":"10.12788\/fp.0463","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T13:13:41Z","timestamp":1714569221000},"source":"Crossref","is-referenced-by-count":1,"title":["EBER-Negative, Double-Hit High-Grade B-Cell Lymphoma Responding to Methotrexate Discontinuation"],"prefix":"10.12788","volume":"41","author":[{"given":"Nhi","family":"Nai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5043","published-online":{"date-parts":[[2024,4,20]]},"container-title":["Federal Practitioner"],"original-title":[],"link":[{"URL":"https:\/\/cdn.mdedge.com\/files\/s3fs-public\/issues\/articles\/0524fed_avaho_methotrexate.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T13:13:41Z","timestamp":1714569221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdedge.com\/fedprac\/avaho\/article\/268618\/oncology\/eber-negative-double-hit-high-grade-b-cell-lymphoma-responding"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,20]]},"references-count":0,"issue-title":["Advances in Hematology and Oncology"],"journal-issue":{"issue":"Supplemental 2","published-online":{"date-parts":[[2024,5,1]]},"published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.12788\/fp.0463","relation":{},"subject":[],"published":{"date-parts":[[2024,4,20]]}}}